Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage

被引：0

作者：

Koga, F. ^{[1
]}

Shirakawa, T. ^{[2
]}

Shimokawa, M. ^{[3
]}

Otsuka, T. ^{[4
]}

Shimokawa, H. ^{[5
]}

Nakazawa, J. ^{[6
]}

Oda, H. ^{[7
]}

Takeshita, S. ^{[8
]}

Kawaguchi, Y. ^{[9
]}

Arita, S. ^{[10
]}

Taguchi, H. ^{[11
]}

Sakai, T. ^{[12
]}

Nishikawa, K. ^{[13
]}

Arima, S. ^{[14
]}

Ueda, Y. ^{[15
]}

Kawahira, M. ^{[16
]}

Sakae, T. ^{[17
]}

Ide, Y. ^{[18
]}

Mizuta, T. ^{[19
]}

Mitsugi, K. ^{[20
]}

机构：

[1] Saga Ken Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, Saga, Japan

[2] Karatsu Higashimatsuura Med Assoc Med Ctr, Internal Med Dept, Saga, Japan

[3] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Ube, Japan

[4] Minato Med Clin, Internal Med, Fukuoka, Japan

[5] JCHO Japan Community Healthcare Org, Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan

[6] Kagoshima City Hosp, Dept Med Oncol, Kagoshima, Japan

[7] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, Kumamoto, Japan

[8] Japanese Red Cross, Dept Gastroenterol, Nagasaki Genbaku Hosp, Nagasaki, Japan

[9] Asakura Med Assoc Hosp, Dept Gastroenterol, Asakura, Japan

[10] Miyazaki Prefectural Miyazaki Hosp, Internal Med & Chemotherapy, Miyazaki, Japan

[11] Imamura Gen Hosp, Dept Gastroenterol, Kagoshima, Japan

[12] Natl Hosp Org, Dept Med Oncol, Kumamoto Med Ctr, Kumamoto, Japan

[13] Oita Univ, Dept Med Oncol & Hematol, Fac Med, Yufu, Japan

[14] Kagoshima Univ, Digest & Lifestyle Dis, Kagoshima, Japan

[15] Japanese Red Cross, Dept Hematol & Oncol, Kumamoto Hosp, Kumamoto, Japan

[16] Kagoshima Kouseiren Hosp, Dept Gastroenterol, Kagoshima, Japan

[17] Saiseikai Sendai Hosp, Dept Gastroenterol, Satsumasendai, Japan

[18] Saga Hosp, Natl Hosp Org, Dept Internal Med, Saga, Japan

[19] Fujikawa Hosp, Dept Internal Med, Saga, Japan

[20] Sasebo Kyosai Hosp, Dept Med Oncol, Sasebo, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

152P

引用

页码：S1534 / S1534

页数：1

共 35 条

[21] Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
Barone, C.
Nuzzo, G.
Cassano, A.
Basso, M.
Schinzari, G.
Giuliante, F.
D'Argento, E.
Trigila, N.
Astone, A.
Pozzo, C.
BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1035 - 1039
[22] Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
C Barone
G Nuzzo
A Cassano
M Basso
G Schinzari
F Giuliante
E D'Argento
N Trigila
A Astone
C Pozzo
British Journal of Cancer, 2007, 97 : 1035 - 1039
[23] A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
Chun, Jung Won
Woo, Sang Myung
Lee, Sang Hyub
Choi, Jin Ho
Park, Namyoung
Kim, Joo Seong
Cho, In Rae
Paik, Woo Hyun
Lee, Woo Jin
Ryu, Ji Kon
Kim, Yong-Tae
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[24] CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) plus bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial
Ziras, N.
Polyzos, A.
Kakolyris, S.
Xenidis, N.
Kentepozidis, N.
Athanasiadis, A.
Stergiou, I.
Androulakis, N.
Vamvakas, L.
Souglakos, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25] Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)
Weinberg, B.
He, A.
Tan, B.
Turk, A.
Noel, M.
Marshall, J.
Sung, M.
Wang, H.
Ferguson, C.
Swanson, N.
Pedersen, K.
ANNALS OF ONCOLOGY, 2023, 34 : S97 - S98
[26] GI-TAC:: A randomised phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid in patients with metastatic upper abdominal (pancreatic-, gastric- or biliary) cancer
Berglund, Ake
Bystrom, Per
Pedersen, Dorte
Nygren, Peter
Frodin, Jan-Erik
Bergman, Antonina
Glimelius, Bengt
ANNALS OF ONCOLOGY, 2006, 17 : 321 - 321
[27] Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases - A Multicenter phase II study by the cancer therapeutic research group
Ho, WM
Ma, B
Mok, T
Yeo, W
Lai, P
Lim, R
Koh, J
Wong, YY
King, A
Leow, CK
Chan, ATC
MEDICAL ONCOLOGY, 2005, 22 (03) : 303 - 312
[28] Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastasesA multicenter phase II study by the cancer therapeutic research group
Wing M. Ho
B. Ma
Tony Mok
W. Yeo
Paul Lai
R. Lim
Jane Koh
Y. Y. Wong
Ann King
C. K. Leow
A. T. C. Chan
Medical Oncology, 2005, 22 : 303 - 312
[29] Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks - A feasibility study in metastatic colorectol cancer patients
Martinez, J
Martin, C
Chacon, M
Korbenfeld, E
Bella, S
Senna, S
Richardet, E
Coppola, F
Bas, C
Hidalgo, J
Escobar, E
Reale, M
Smilovich, AM
Wasserman, E
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (01): : 45 - 51
[30] Folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus chemoradiation (CRT) with 5-fluorouracil (5FU) as adjuvant treatment for patients with operable gastric cancer (OGC): A feasibility study with pharmacogenetic analysis
Athanasiadis, A.
Boukovinas, I.
Sfakianaki, M.
Saridaki, Z.
Papadaki, C.
Tzardi, M.
Androulakis, N. E.
Polyzos, A.
Georgoulias, V.
Sougklakos, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)

← 1 2 3 4 →